[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Priovant Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100633893","phase-2-a-phase-23-study-of-brepocitinib-in-adults-with-lichen-planopilaris-100633893",false,"NCT07532603","A Phase 2\u002F3 Study of Brepocitinib in Adults With Lichen Planopilaris","A Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris","ALPINE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Scalp biopsy consistent with LPP\n3. Active and symptomatic LPP at screening and baseline-\n4. Weight \\> 40 kg to \\\u003C 130 kg with BMI ≤ 45 kg\u002Fm2\n\nExclusion Criteria:\n\n1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).\n2. High risk of thrombosis or cardiovascular disease\n3. High risk of herpes zoster\n4. Active or recent infection","ALL","18 Years",{"count":20,"type":21},342,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris",[28],"Lichen Planopilaris",[30,31],"brepocitinib","lichen planopilaris","RECRUITING","2026-04-09",{"date":35,"type":36},"2026-04-16","ACTUAL",{"date":38,"type":36},"2026-03-19",{"date":40,"type":21},"2029-07-31",{"name":42,"class":43},"Priovant Therapeutics, Inc.","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100591307","phase-2-a-phase-2-study-of-the-safety-and-efficacy-of-brepocitinib-in-adults-with-cutaneous-sarcoidosis-beacon-100591307","NCT06978725","A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis","BEACON","Inclusion Criteria:\n\n1. Adults subjects (18-74)\n2. Cutaneous sarcoidosis with characteristic skin biopsy histology\n3. A CSAMI activity score ≥ 10\n4. Weight \\> 40 kg to \\\u003C 130 kg with BMI \\\u003C 40 kg\u002Fm2 .\n\nExclusion Criteria\n\n1. History of\n\n   * Lymphoproliferative disorder\n   * Active malignancy;\n   * History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).\n2. High risk of thrombosis or cardiovascular disease\n3. High risk of herpes zoster\n4. Active or recent infection","75 Years",{"count":55,"type":21},28,[24],"This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.",[59],"Cutaneous Sarcoidosis",[61,62,30],"sarcoidosis","cutaneous sarcoidosis","2025-05-09",{"date":65,"type":36},"2025-05-18",{"date":67,"type":36},"2025-04-09",{"date":69,"type":21},"2026-12",{"name":42,"class":43},4,""]